Worst-rank score analysis with informatively missing observations in clinical trials.
about
The feasibility of Whole Body Vibration in institutionalised elderly persons and its influence on muscle performance, balance and mobility: a randomised controlled trial [ISRCTN62535013]A randomised, controlled study on the effects of a short-term endurance training programme in patients with major depressionProblems in dealing with missing data and informative censoring in clinical trials.Randomized trial of acetylcysteine in idiopathic pulmonary fibrosisAre missing data adequately handled in cluster randomised trials? A systematic review and guidelines.Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals.Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.An optimal Wilcoxon-Mann-Whitney test of mortality and a continuous outcome.Intent-to-randomize corrections for missing data resulting from run-in selection bias in clinical trials for chronic conditions.Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trialInjectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.Pentoxifylline, inflammation, and endothelial function in HIV-infected persons: a randomized, placebo-controlled trialDevelopment of an orogastrointestinal mucosal model of candidiasis with dissemination to visceral organs.Evaluating the evaluation.Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis.Would loss to follow-up bias the outcome evaluation of patients operated for degenerative disorders of the lumbar spine?Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.Treatment moderators and predictors of outcome in the Treatment of Early Age Mania (TEAM) studyPreventing smoking relapse via Web-based computer-tailored feedback: a randomized controlled trialComparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis.Eliciting and using expert opinions about dropout bias in randomized controlled trials.Effects of prior intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes in the DCCT/EDIC.Anidulafungin treatment of candidal central nervous system infection in a murine modelRe: Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review.Interpretation of patient-reported outcomes.Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia.Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Predictors of 6-month health utility outcomes in survivors of acute respiratory distress syndrome.Inference in randomized trials with death and missingness.Experimental evidence that granulocyte transfusions are efficacious in treatment of neutropenic hosts with pulmonary aspergillosis.Health-promoting interventions for persons aged 80 and older are successful in the short term--results from the randomized and three-armed Elderly Persons in the Risk Zone study.Efficacy of posaconazole in a murine model of central nervous system aspergillosis.Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.One-year outcomes of rosuvastatin versus placebo in sepsis-associated acute respiratory distress syndrome: prospective follow-up of SAILS randomised trial.Assessment of the paradoxical effect of caspofungin in therapy of candidiasisExperimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.Power and sample size calculations for the Wilcoxon-Mann-Whitney test in the presence of death-censored observations.Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis.Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods.
P2860
Q21261854-E3D11DB0-7526-480E-8328-97E0A12C43C2Q24642442-4577B803-6242-43E4-B8EF-7629E7D8827EQ24794267-33A7F3EE-333D-4EE7-BA13-707C633BDC5EQ28240218-B1B924C5-225D-4EAB-8746-685BE3E91AD9Q30829258-36852739-7CC4-44D5-B360-BD6526D425D1Q31016853-57B846B7-2452-42F5-B09C-D2B9EBDCCE42Q31030917-B314A55F-5832-4AC9-9AD2-1BE91F22DEBCQ33569474-1B775F85-2B46-47F4-A728-5FA28C666634Q33842428-0E2013FE-E5B8-44CE-B97B-B81AF9F70295Q34031302-B202FADE-0729-4F9C-9308-8E568FEC442DQ34357213-E4E30E4B-5123-429D-953B-4FB398C65287Q34674223-AF22B080-AB9A-47BC-8E5F-51AEDD21CB24Q34973812-E4A4B258-3784-49A1-9BD1-698B36A1BA5EQ35043290-0283C497-E3B1-4180-A2D2-107D2D9CFD14Q35121804-B50047EB-7F7E-4A61-A5D5-81B0CAA068A4Q35590548-F42E811D-DBF1-42CB-809C-6F962EEB6071Q35825613-66A3CFEC-3D6C-4332-9A18-709CB84DD03DQ36188647-75BF12FB-F59A-4420-8D74-A1E7D9113E86Q36435585-58E4D01D-CEB0-4DCF-A69E-E945C1D27F46Q36489697-2673F62C-F6DC-47AF-AF06-6824FA715D80Q36800618-EEBBB27B-EC5A-4816-887E-E914B603007FQ37193344-57A31262-9E52-45DC-B7C4-629298CEC99AQ37274734-6693F13C-654B-4B67-A72B-1D75C3F9334EQ38075414-C19E843E-F445-43DE-8865-B4234237DE1EQ38083263-1BA2EE37-2A0A-42AD-A9FA-6DFAFFDDF61FQ38255164-AA520CD1-8A45-43D3-B445-69B6538A5204Q38374127-916BD57A-4580-4353-8299-6C1A5B91AF34Q38389314-BB494381-8589-4C5F-9AA2-B6BD79EAF25DQ38839558-F87FB4A0-3FDA-4B66-A6DD-9AD284B9CFCCQ39278824-5B104EB5-8841-46CC-A86E-AC9B9E37ADB1Q39765887-80104120-8D1F-4625-9E1F-13191C7978DCQ40025840-456E33FB-AB48-4A48-8B57-5722C01CE10EQ40164914-C76E58F1-B05E-42F8-AE5E-7BB40F463CC2Q40667866-0CE717A6-F538-4B13-8A99-E332B8A47C2EQ40769656-C7258DEF-CA91-482C-8A2E-85FF31C1238CQ42090519-348C68A9-1F97-4F64-87DB-EDEAFE4592B8Q42217419-E822E30C-11A9-4D34-8F3C-057A981109D1Q42266334-3E20F1F0-89A2-461E-B543-7E1AA793E08AQ42554139-C11EF7DB-A7C9-4D9D-8892-CCA511E875B5Q42708837-C0945082-5D65-4CF5-970B-B69AA0C787E3
P2860
Worst-rank score analysis with informatively missing observations in clinical trials.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Worst-rank score analysis with informatively missing observations in clinical trials.
@ast
Worst-rank score analysis with informatively missing observations in clinical trials.
@en
type
label
Worst-rank score analysis with informatively missing observations in clinical trials.
@ast
Worst-rank score analysis with informatively missing observations in clinical trials.
@en
prefLabel
Worst-rank score analysis with informatively missing observations in clinical trials.
@ast
Worst-rank score analysis with informatively missing observations in clinical trials.
@en
P1476
Worst-rank score analysis with informatively missing observations in clinical trials.
@en
P2093
P304
P356
10.1016/S0197-2456(99)00022-7
P407
P577
1999-10-01T00:00:00Z